Omeros Corporation logo
Omeros Corporation OMER
$ 18.95 0.15%
report update icon

Quarterly report 2026-Q2
added 08-12-2026

Omeros Corporation Income Statement 2025-2008 | OMER

Brief overview of financial results at Omeros Corporation

This overview is based on financial performance over the past five years. According to figures from Omeros Corporation, revenue changed from $539 thousand to $112 million over five years. The cumulative result was +20643%, corresponding to roughly 190.7% per year. The annual growth rate indicates an exceptionally strong top-line trend.

Over the period, EBITDA shifted from −69.7 million dollars to −61.6 million dollars, a change of +11.6%. Changes in revenue did not translate into comparable EBITDA performance. Comparing the endpoints gives EBITDA margins of −12928% and −55.1%. Higher profitability strengthens the quality of operating growth.

Across the five years, the net result shifted from −$73.7 million to −$84.5 million. The loss widened and increased the financial risk.

The five-year change in capitalization reached −12.5%: from 739 million dollars to 647 million dollars. The market became more cautious about the prospects of the business.

What the figures show

Positive developments coexist with areas of weakness. The financial profile benefits from positive operating leverage and sales growth. The most visible risks are a narrow EBITDA buffer and declining net profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Omeros Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

671 M 478 M 200 M 215 M 401 M 817 M 647 M 636 M 755 M 375 M 405 M 739 M 342 M 133 M 129 M 118 M - -

Shares

63.5 M 58.2 M 62.7 M 62.7 M 62.3 M 57.2 M 49.5 M 48.6 M 45.5 M 40.4 M 37.6 M 33.2 M 28.6 M 24.2 M 22.2 M 21.4 M - -

Historical Prices

10.6 8.22 3.19 3.43 6.43 14.3 14.1 11.1 19.4 9.92 15.7 24.8 11.3 5.19 3.95 5.52 - -

Net Income

-3.35 M -157 M -118 M 47.4 M 194 M -138 M -84.5 M -127 M -53.5 M -66.7 M -75.1 M -73.7 M -39.8 M -38.4 M -28.5 M -29.3 M -21.1 M -

Revenue

- - - - - - 112 M 29.9 M 64.8 M 41.6 M 13.5 M 539 K 1.6 M 6.02 M 4.52 M 2.1 M 1.44 M -

Cost of Revenue

- - - - - - 865 K 512 K 1.08 M 1.41 M - - - - - - - -

Gross Profit

- - - - - - 111 M 29.4 M 63.7 M 40.2 M 12.5 M - - - 4.52 M - - -

Operating Income

-123 M -167 M -165 M -163 M -174 M -157 M -146 M -112 M -43.9 M -54.3 M -71.2 M -70 M -50.5 M -36.9 M -27.4 M -30.1 M -20.8 M -

Interest Expense

- - 30.8 M 22.7 M 19.7 M 26.8 M 22.7 M 16.3 M 11 M 7.82 M 3.57 M 3.47 M 2.37 M 1.73 M 1.88 M 1.54 M 2.2 M -

EBITDA

-122 M -166 M -164 M -162 M -172 M -155 M -61.6 M -111 M -43.3 M -54 M -71 M -69.7 M -50.2 M -36.6 M -27 M -29.6 M -20.3 M -

Operating Expenses

- - - - - - 174 M 142 M 108 M 94.5 M 83.7 M 70.5 M 52.1 M 42.9 M 31.9 M 32.2 M 22.2 M -

General and Administrative Expenses

41.5 M 47.4 M 49.7 M 50.7 M 54.8 M 49.3 M 64.6 M 51.7 M 52 M 43.8 M 35.3 M 22.6 M 15.8 M 11 M 8.22 M 8.75 M 5.27 M -

All numbers in USD currency

Quarterly Income Statement Omeros Corporation

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

58.6 M 71.9 M - 66.3 M 58.6 M 58.1 M 58 M 57.9 M 57.9 M 58.8 M 61.1 M 62.9 M 62.8 M 62.8 M 62.8 M 62.7 M 62.7 M 62.7 M 62.6 M 62.5 M 62.4 M 61.9 M 61.7 M 58.2 M 54.5 M 54.3 M 54.2 M 49.4 M 49.1 M 49 M 49 M 48.6 M 48.4 M 48.3 M 48.2 M 46.3 M 44 M 43.8 M 43.8 M 41.1 M 39.2 M 38.3 M 38 M 37.9 M 37.8 M 36.5 M 34.2 M 34 M 33.9 M 30.9 M 30.4 M 29.8 M 28.2 M 25.9 M 25.9 M 25.8 M 22.5 M 22.4 M 22.4 M 22.2 M 22.2 M 22.4 M

Net Income

-33.5 M 56.1 M - -30.9 M -25.4 M -33.5 M - -32.2 M -56 M -37.2 M - -37.8 M -37.3 M -33.7 M - -17.5 M -30.8 M -33 M - -22.7 M -28.6 M -35.1 M -37.3 M -38.5 M -33.3 M -29 M -29.2 M -16.5 M -14.5 M -24.3 M -23.5 M -39.5 M -33.7 M -30.1 M -16.6 M -7.48 M -14.4 M -53.5 M -19.6 M -14 M -66.7 M 66.7 M -19.8 M -19.9 M -16.7 M -18.7 M -20.7 M -18.3 M -18 M -16.6 M -1.84 M -13.9 M -13.6 M -10.5 M -7.73 M -13.3 M -8.54 M -8.9 M -10.2 M -6.51 M -5.29 M -6.54 M

Revenue

- 9.89 M - - - - - - - - - - - - - - - - - 30 M 28.8 M 21.1 M 10.6 M 26.1 M 13.5 M 23.5 M 33.4 M 29.9 M 26.8 M 21.8 M 22 M 4.61 M 1.66 M 1.59 M 13.8 M 21.7 M 17.2 M 12.3 M 12.9 M 11.3 M 10 M 7.42 M 6.68 M 3.26 M 3.19 M 388 K 180 K 214 K 45 K 100 K 169 K 196 K 140 K 1.1 M 1.58 M 1.42 M 1.53 M 1.5 M 1.14 M 987 K 1.16 M 1.24 M

Cost of Revenue

- 587 K - - - - - - - - - - - - - - - - - 333 K 342 K 263 K - 401 K 147 K 267 K - 278 K 55 K 131 K - 36 K 116 K 203 K - 184 K - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-32.4 M -17.4 M - -26.4 M -32.4 M -35 M - -35.4 M -59.2 M -39 M - -48.2 M -40.9 M -35.7 M - -50.8 M -37.4 M -35 M - -39.8 M -45.6 M -45.3 M -33.8 M -25.4 M -27.7 M -23.7 M -23.7 M -11.1 M -63.4 M -63.4 M -18.5 M -35.4 M -30.6 M -27.7 M -14.1 M -5.11 M -11.9 M -12.7 M -11.9 M -12 M -10.9 M -19.5 M -18 M -19.3 M -16 M -17.9 M -20 M -17.1 M -17.2 M -15.7 M -13.9 M -13.4 M -13.2 M -10 M -7.53 M -13 M -8.24 M -8.07 M -9.85 M -6.16 M -4.95 M -6.45 M

Interest Expense

- - - - - - - 4.05 M 9.22 M 8.23 M - 7.92 M 7.93 M 7.93 M - 4.93 M 4.93 M 4.94 M - 4.91 M 4.91 M 4.9 M - 6.88 M 5.98 M 5.9 M - 5.72 M 5.53 M 5.6 M - 4.6 M 3.68 M 2.82 M - 2.78 M 2.72 M 2.66 M - 2.14 M 1.86 M 1.38 M - 871 K 937 K 957 K - 944 K 939 K 672 K - 592 K 589 K 587 K - 413 K 453 K 494 K - 528 K 527 K 293 K

EBITDA

-32.2 M -17.2 M - -26.2 M -32.2 M -34.7 M - -35.2 M -59 M -38.8 M - -48 M -40.6 M -35.5 M - -50.5 M -37.2 M -34.8 M - -39.5 M -45.2 M -44.9 M -33.8 M -25 M -27.3 M -23.3 M -23.7 M -10.7 M -62.6 M -63 M -18.5 M -34.8 M -30.2 M -27.5 M -14.1 M -4.73 M -11.7 M -12.6 M -11.9 M -11.8 M -10.8 M -19.4 M -18 M -19.1 M -15.9 M -17.9 M -20 M -16.9 M -17.1 M -15.6 M -13.9 M -13.2 M -13 M -9.95 M -7.53 M -12.8 M -8.08 M -7.98 M -9.85 M -5.83 M -4.72 M -6.28 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - 41 M 40.5 M 40 M 32.3 M 29.3 M 27.9 M 26.8 M 29.1 M 25 M 24.8 M 23.3 M 20.9 M 26.9 M 24.7 M 22.6 M 19.2 M 18.3 M 20.2 M 17.3 M 17.3 M 15.8 M 14.1 M 13.6 M 13.3 M 11.1 M 9.12 M 14.5 M 9.77 M 9.57 M 11 M 7.15 M 6.1 M 7.69 M

General and Administrative Expenses

10.3 M 13.4 M - 10.4 M 10.3 M 11.1 M - 11.3 M 13.8 M 12.3 M - 16.4 M 11.3 M 11.1 M - 12.2 M 13.9 M 11 M - 14 M 15.5 M 12.8 M - 19.8 M 16.9 M 18 M - 16.9 M 16.9 M 14.6 M - 13.2 M 12.7 M 10.9 M - 11.7 M 15.8 M 12.5 M - 10.5 M 10.4 M 11.1 M - 9.05 M 7.89 M 8.99 M - 5.57 M 4.86 M 3.77 M - 4.21 M 3.74 M 3.99 M - 2.74 M 2.21 M 2.32 M - 1.83 M 2.03 M 2.26 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Omeros Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Codexis Codexis
CDXS
$ 1.46 2.82 % $ 127 M usaUSA
Ardelyx Ardelyx
ARDX
$ 3.78 1.89 % $ 911 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.9 1.01 % $ 3.04 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 36.6 1.3 % $ 410 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 7.12 6.91 % $ 4.76 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 206.68 0.16 % $ 10.3 B usaUSA
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 56.8 0.94 % $ 1.63 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 66.53 0.15 % $ 12.8 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 4.3 1.42 % $ 298 M britainBritain
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA